Botox for Crow's Feet: Units, Cost, Approved Toxins, and When Laser or Filler Wins

When you smile, laugh, or squint against bright sunlight, fan-shaped lines naturally radiate outward from the outer corners of your eyes. Known medically as lateral canthal rhytides and colloquially as crow's feet, these dynamic creases are among the earliest and most common facial aging changes that lead patients to consider aesthetic procedures.

While botulinum toxin injection is universally recognized as the first-line medical intervention for crow's feet, the treatment landscape contains critical clinical nuances that standard provider marketing routinely glosses over:

1. The FDA Approval Gap: Despite six neurotoxins competing in the United States aesthetic market, only two products—Botox Cosmetic (onabotulinumtoxinA) and Xeomin (incobotulinumtoxinA)—hold FDA-approved indications for lateral canthal lines. Competitors like Dysport, Jeuveau, Daxxify, and Letybo are used in this region off-label.
2. The 24-Unit Label Standard: The official FDA-approved dosing protocol across both approved labels is 24 units total (12 units per eye distributed across three discrete injection sites).
3. The Dynamic vs. Static Fork: Neuromodulators relax hyperactive muscle fibers to soften lines formed during facial expression (dynamic lines). They cannot erase deeply etched creases that remain etched in the skin when your face is completely relaxed (static lines). Treating static lines with higher neurotoxin doses risks frozen expressions and eyelid complications; structural skin texturing requires resurfacing lasers, chemical peels, or topical retinoids.
4. The "No-Cream" Reality: At least nine registered clinical trials evaluated topical botulinum toxin gels and creams for crow's feet; every program failed to achieve commercial approval because large neurotoxin protein complexes cannot penetrate the intact stratum corneum barrier.

Understanding exact injection geometry, realistic pricing mechanics, onset timelines, periorbital safety risks, and the decision fork between neurotoxins, lasers, and fillers is essential before scheduling treatment.

---

Direct Answer: How Does Botox for Crow's Feet Work?

For someone evaluating treatment for lateral canthal lines:

• What it does: Low-dose neurotoxin relaxes the lateral portion of the orbicularis oculi sphincter muscle, preventing the skin bunching that causes lines when smiling or squinting.
• On-label toxins: Only Botox Cosmetic and Xeomin carry FDA approval for moderate-to-severe lateral canthal lines. Dysport, Jeuveau, Daxxify, and Letybo are clinically effective but off-label for this area.
• Standard dosing: The FDA on-label dose is 24 units total (12 units per eye, split into 3 injection sites of 4 units each). Customized dosing ranges from 8 to 16 units per eye depending on muscle strength, age, and sex.
• Real-world cost: At typical market rates of $10 to $25 per unit, a full 24-unit treatment costs $240 to $600 per session. Flat per-area rates typically range from $250 to $500. The American Society of Plastic Surgeons (ASPS) 2023 statistics report lists a national average physician fee for botulinum toxin of $697 (representing a member-surgeon average across treatment sessions).
• Longevity: Visible softening begins within 3 to 5 days, reaching maximum clinical effect at day 14 and lasting 3 to 4 months. Highly expressive patients may see movement return sooner due to frequent involuntary blinking.
• Lines at rest: Neurotoxin stops the folding action; it does not fill or resurface etched dermis. For static lines visible at rest, fractional laser resurfacing, medium chemical peels, or prescription tretinoin are the correct evidence-based choices. Dermal filler should generally be avoided in lateral crow's feet lines due to risks of superficial lumps, Tyndall effect, and lymphatic disruption.

---

Anatomy of Crow's Feet: Dynamic vs. Static Rhytides

The skin surrounding the human orbit is the thinnest on the body (approximately 0.3 to 0.5 mm thick) and contains minimal subcutaneous adipose tissue. Lateral canthal lines develop as a direct consequence of this delicate anatomy interacting with repetitive muscular kinetics and chronological skin aging.

The Muscular Culprit: Orbicularis Oculi

The primary anatomical driver of crow's feet is the orbicularis oculi, a complex circular sphincter muscle that surrounds each orbit. The muscle is divided into three distinct anatomical zones:

1. Palpebral portion (pretarsal and preseptal): Responsible for gentle, involuntary blinking and tear pumping.
2. Orbital portion: The broader outer ring that extends over the temple, eyebrow, and upper cheek. Vigorous contraction of the lateral orbital fibers (during smiling, grimacing, or squinting) pulls the temple and cheek skin medially toward the eye, bunching the overlying dermis into characteristic radiating folds.
3. Zygomaticus major & minor interaction: At the lower-lateral canthal junction, the orbicularis oculi interlaces with the upper cheek elevators. In hyperdynamic smiles, cheek elevation pushes skin upward into the orbital rim.

The Critical Diagnostic Fork: Dynamic vs. Static Creases

---

Which Neurotoxins Are FDA-Approved for Crow's Feet?

A critical distinction that patients rarely discover on med-spa websites is the regulatory status of each injectable neuromodulator. While all FDA-approved neurotoxins utilize botulinum neurotoxin type A to cleave the SNAP-25 protein and prevent acetylcholine vesicle fusion, they carry distinct clinical indications on their official prescribing information.

The six aesthetic toxins all carry FDA approval for glabellar (frown) lines; only Botox Cosmetic and Xeomin added the lateral canthal indication. For off-label products, no canthal dose exists on any label, and unit systems differ between brands — see every FDA-approved neurotoxin compared for the full product-by-product map.

The 2022 Xeomin Approval Milestone

In 2022, Xeomin achieved a significant regulatory milestone by becoming the first and only neurotoxin formally FDA-approved for the simultaneous treatment of all three upper facial areas (moderate-to-severe horizontal forehead lines, glabellar frown lines, and lateral canthal lines) in a single session, capped at a maximum cumulative dose of 64 units.

This expanded approval was supported by two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (NCT04594213 / Trial 1071 and NCT04622254 / Trial 1070), which evaluated 730 subjects. The trials proved that treating the lateral canthal lines concurrently with the glabella and forehead produced harmonious upper-facial rejuvenation without increasing adverse events.

Understanding "Off-Label" Use

Off-label use of Dysport, Jeuveau, Daxxify, and Letybo for crow's feet is common, legal, and widely practiced by board-certified dermatologists and plastic surgeons. It simply means the pharmaceutical manufacturer did not submit the specific multi-million-dollar clinical trial package required to add the lateral canthal line string to its FDA-approved package insert. However, when comparing products, patients should recognize that dosing units are not interchangeable across brands (e.g., 1 unit of Botox does not equal 1 unit of Dysport). For a complete breakdown of molecular structures, see every FDA-approved neurotoxin compared.

---

Units, Injection Geometry, and Cost Math

Precision in crow's feet injection is defined by three strict parameters: injection site placement, depth of needle insertion, and total unit volume.

                   [The 3-Point Injection Geometry]

                 Site 1: Superior Lateral (4 Units)
                    ▲  • Located ~1.0–1.5 cm outside lateral orbital rim
                    │  • Placed at or slightly above the lateral canthus line
                    │
   Lateral Canthus ─┼─► Site 2: Central Lateral (4 Units)
                    │  • Directly lateral to the outer eye corner
                    │  • Injected superficially into the subdermal plane
                    ▼
                 Site 3: Inferior Lateral (4 Units)
                       • Located ~1.0–1.5 cm outside inferior orbital rim
                       • Caution: Kept high enough to avoid zygomaticus major

The On-Label Injection Pattern

On both the Botox Cosmetic and Xeomin prescribing labels, the standardized injection protocol requires:

• Total Dose: 24 Units total.
• Per Eye: 12 Units per side.
• Site Distribution: 3 discrete injection points of 4 units each per side (6 total injection points).
• Anatomical Safety Boundary: Injections are placed approximately 1.5 cm lateral to the lateral canthus — outside the bony orbital rim. Injecting inside the bony rim allows toxin to diffuse through the orbital septum into the delicate extraocular muscles and lacrimal glands.
• Injection Depth: Extremely superficial—subdermal or superficial intramuscular (wheal-like bleb). Because the orbicularis oculi lies immediately beneath the translucent dermis, deep intramuscular injections risk penetrating deeper facial vessels and underlying zygomatic musculature.

Dosing Variations: Tailoring to Patient Anatomy

These ranges are injector practice patterns, not label dosing. The only FDA-labeled canthal dose is the 24-unit Botox Cosmetic / Xeomin pattern; actual treatment is individualized by anatomy, muscle strength, and provider judgment — which is precisely the conversation to have with your injector before treatment.

Pricing Mechanics: Per-Unit vs. Per-Area Billing

Aesthetic practices generally bill neuromodulators using one of two pricing structures:

[Pricing Frameworks for 24-Unit Crow's Feet]

1. Per-Unit Model:
   24 Units × $10/unit ────────────────────────── $240 (Lower Market / Specials)
   24 Units × $15/unit ────────────────────────── $360 (National Median)
   24 Units × $25/unit ────────────────────────── $600 (Metro Derm/Plastics Specialists)

2. Per-Area Flat Fee Model:
   Crow's Feet Single Zone ────────────────────── $250 to $500 (Flat Fee)

3. National Surgical Benchmark:
   ASPS 2023 Statistics Report Average ───────── $697 (Physician Member-Surgeon Average)

1. Per-Unit Pricing: You pay strictly for the number of units reconstituted and injected. In the United States, per-unit rates typically range from $10 to $25 per unit. A standard 24-unit treatment costs between $240 and $600.
2. Per-Area Flat Fees: The provider charges a set price per facial zone (e.g., glabella = 1 area; crow's feet = 1 area), regardless of whether you receive 18 or 24 units. Flat fees typically range from $250 to $500 per area.
3. The ASPS National Benchmark: The American Society of Plastic Surgeons (ASPS) 2023 Plastic Surgery Statistics Report records an average physician fee of $697 for botulinum toxin procedures. (Note: This reflects a national average across member plastic surgeons for typical multi-area treatment sessions and excludes standalone med-spa discount promotions). For a full breakdown of pricing strategies, see how Botox is priced per unit versus per area.

---

Onset, Duration, and Recovery

The clinical trajectory of lateral canthal neurotoxin treatment follows a predictable timeline:

Day 0: Injection ──► Minor pinpoint erythema & wheals resolve in 30–60 minutes
Day 3–5: Initial Onset ──► First noticeable reduction in dynamic skin bunching
Day 14: Peak Clinical Effect ──► Maximum muscle relaxation and line smoothing
Month 2–3: Gradual Recovery ──► Subtle return of expressive movement
Month 3–4: Full Duration Limit ──► Muscle tone recovers; time for maintenance retreatment

• Days 1 to 3 (Post-Procedure): Mild pinpoint swelling and localized redness at the six injection sites resemble tiny mosquito bites and resolve within 30 to 60 minutes. Bruising is the most common local reaction, reported at rates above 1% in the upper-facial-line label trials.
• Days 3 to 5 (Initial Action): Patients notice that the outer eye corners feel slightly relaxed when smiling in the mirror.
• Day 14 (Full Assessment): Neurotoxin binding and SNAP-25 cleavage reach peak therapeutic saturation. Any touch-ups or asymmetry corrections should only be performed after day 14.
• Duration (3 to 4 Months): The average duration of crow's feet relaxation is 3 to 4 months.

Why Crow's Feet Wear Off Faster Than Forehead Lines

Many patients observe that their crow's feet return sooner (often around 2.5 to 3 months) than their glabellar frown lines. This is biologically normal:

1. High Involuntary Contraction Frequency: Humans blink involuntarily 15 to 20 times per minute (over 14,000 times per waking day), subjecting the orbicularis oculi to near-continuous muscular activity that accelerates collateral nerve sprouting and neuromuscular junction recovery.
2. Lower Total Dose Density: The orbicularis oculi receives a lower concentration of units relative to its wide surface area compared to the dense, thick muscle bundles of the corrugators. For more on duration dynamics across facial zones, see how long Botox lasts by area.

---

What to Do When Lines Stay at Rest: Laser, Peels, or Skincare vs. Filler

One of the most frequent clinical missteps in periorbital aesthetics is attempting to use neurotoxins or dermal fillers to eliminate lines that remain visible when the face is at rest (static rhytides).

                            [The Periorbital Treatment Fork]
                                          │
                  Are lines present only when smiling / squinting?
                                          │
                         ├──► YES: Dynamic Lines
                         │          • Primary Treatment: Neurotoxin (Botox / Xeomin)
                         │          • Target: Orbicularis Oculi Muscle
                         │
                         └──► NO: Static Lines Etched at Rest
                                    • Primary Treatment: Dermal Resurfacing & Collagen Induction
                                    • 1. Fractional Lasers (CO2, Erbium, Moxi)
                                    • 2. Medium Chemical Peels (TCA / Jessner's)
                                    • 3. Prescription Topical Retinoids (Tretinoin)
                                    • (AVOID: Direct Dermal Filler Injections in Crow's Feet)

Why Dermal Fillers Rarely Belong in Crow's Feet

Patients frequently ask whether hyaluronic acid (HA) dermal filler can be injected directly into crow's feet lines like a spackle over drywall. In modern aesthetic medicine, injecting dermal filler directly into lateral canthal lines is strongly discouraged by experienced injectors:

• The Tyndall Effect: The periorbital skin is gossamer-thin. Even micro-droplets of HA filler placed too superficially scatter blue light, creating persistent, disfiguring blue-gray discoloration beneath the skin.
• Superficial Nodules & Lumping: Smiling causes dynamic compression that displaces filler into visible surface beads.
• Lymphatic Obstruction & Malar Edema: Hyaluronic acid is hydrophilic (water-binding). Placing filler near the lateral canthus compresses superficial lymphatic drainage pathways, causing chronic under-eye bags and puffy malar festoons that require hyaluronidase dissolution.

The Evidence-Based Solutions for Static Crow's Feet

1. Fractional Laser Resurfacing:
   • Non-Ablative Fractional Lasers (1550 nm / 1927 nm, e.g., Fraxel, Moxi): Create microscopic thermal zones in the periorbital dermis, triggering heat-shock proteins and neocollagenesis without breaking the stratum corneum. Requires 3 to 4 sessions with 2 to 3 days of mild redness.
   • Ablative Fractional Lasers (Fractional CO₂ or Er:YAG): Vaporize microscopic dermal columns to physically tighten loose periorbital skin and erase deep dermal cross-hatching. Represents the gold standard for severe photoaging, with 5 to 7 days of downtime. Compare modalities in our guide on peel versus laser for resurfacing.
2. Medium-Depth Chemical Peels:
   • Formulations combining Jessner's Solution with 15%–20% Trichloroacetic Acid (TCA) or targeted periorbital phenol-croton oil micro-peels denature solar-damaged epidermal proteins and stimulate organized type I collagen synthesis in the papillary dermis.
3. Prescription Topical Retinoids:
   • Daily application of topical tretinoin (0.025% to 0.05%) upregulates procollagen gene expression and inhibits matrix metalloproteinases (MMPs) that degrade dermal elastin.

---

Why Is There No Botox Cream? The Failed Topical Trials

A perpetual question in cosmetic dermatology is why patients must undergo needle injections when a topical cream would be far more convenient. The answer lies in the fundamental biophysics of transdermal drug delivery.

The 500-Dalton Molecular Weight Barrier

The human stratum corneum is designed to prevent foreign biological macromolecules from entering the body. Under Bos and Meinardi's 500-Dalton Rule, topical compounds must have a molecular weight under 500 Daltons (Da) and high lipophilicity to passively penetrate intact skin.

• Tretinoin: ~300 Da (penetrates skin).
• Botulinum Neurotoxin Type A core protein: 150,000 Da (150 kDa).
• Botox native progenitor complex (with hemagglutinin proteins): 900,000 Da (900 kDa).

The botulinum toxin protein complex is roughly 1,800 times larger than the maximum molecular size capable of passive transdermal penetration.

[Molecular Scale Comparison]
  Stratum Corneum Penetration Limit: ── 500 Da
  Tretinoin Molecule:                 ── 300 Da    (Passes easily)
  Botulinum Toxin Core (150 kDa):     ──────────────────────────────────────────► 150,000 Da  (BLOCKED)
  Botox Progenitor Complex (900 kDa): ────────────────────────────────────────────────────────────────────────► 900,000 Da

The Clinical Trial Evidence: 9 Registered Topical Toxin Trials

Pharmaceutical companies invested heavily attempting to engineer peptide-chaperone and synthetic transdermal carrier systems for topical botulinum toxin.

Data from the ClinicalTrials.gov registry confirms that at least nine registered clinical trials evaluated topical botulinum formulations specifically for lateral canthal lines:

• The RT001 Topical Gel Program (Revance Therapeutics): Evaluated daxibotulinumtoxinA bound to a proprietary positive-charged synthetic peptide carrier (TransMTS) in eight clinical trials (including NCT00968825, NCT01124552, and NCT01064518). Phase 2 trials showed modest localized muscle relaxation, but the Phase 3 REALISE trial in lateral canthal lines (2016) did not achieve its co-primary endpoints versus vehicle, and Revance discontinued the topical crow's-feet program.
• The ANT-1207 Program (Anterios / Allergan): Evaluated topical botulinum toxin Type A formulated with a synthetic lipid-matrix carrier (NCT01358695). The program stalled in early-phase development.

These trials established that delivering a 150 kDa neurotoxin through the epidermal barrier to reach the orbicularis oculi muscle uniformly requires percutaneous needle delivery.

---

Eye-Area Risks, Complications, and Non-Candidates

While crow's feet injections are exceptionally safe when performed by experienced anatomists, the periorbital zone contains vital neuromuscular and ocular structures.

                    [Periorbital Safety Risk Map]
                                  
                       Superior Spread Risk
                       ├── Deep injection diffusion through orbital septum
                       └── Eyelid Ptosis (Levator Palpebrae Superioris weakness)
                                  │
    Medial Diffusion Risk ────────┼──────── Lateral Safety Zone (SAFE)
    ├── Lacrimal Gland diffusion  │         • Injections strictly ≥1.0–1.5 cm
    │   └── Severe Dry Eye        │           outside the bony orbital rim
    └── Lateral Rectus diffusion  │         • Superficial subdermal wheals
        └── Diplopia (Double Vis) │
                                  │
                       Inferior Spread Risk
                       ├── Injections placed too low / deep into cheek
                       └── Zygomaticus weakness ──► Asymmetric smile / mouth droop

Common vs. Severe Adverse Effects

The Snap-Back Test: Screening for Lower Lid Laxity

Prior to placing any neurotoxin in the lower crow's feet region, a clinician should perform the lower eyelid snap-back test:

1. The injector pinches the lower eyelid skin downward away from the globe and releases it.
2. If the eyelid snaps back against the eye instantly without blinking, muscle tone is intact.
3. If the eyelid returns slowly or requires a voluntary blink to snap back (delayed snap-back), the patient has subclinical lower lid laxity. Paralyzing the orbicularis in this patient will induce ectropion (eyelid eversion), scleral show, and chronic tearing.

Who Should Avoid Crow's Feet Toxin (Contraindications)

• Pre-existing Severe Dry Eye Syndrome: Patients with severe Sjögren's syndrome, chronic meibomian gland disease, or corneal ulcerations.
• Neuromuscular Disorders: Myasthenia Gravis, Lambert-Eaton syndrome, or Amyotrophic Lateral Sclerosis (ALS), where neurotoxins can precipitate systemic weakness or dysphagia.
• Active Infection: Active herpes zoster ophthalmicus, cellulitis, or blepharitis near the injection sites.
• Pregnancy and Breastfeeding: Safety has not been established in clinical trials; treatment is contraindicated.

---

Frequently Asked Questions

Is 20 units enough for crow's feet?

Yes. While the official FDA-approved label dosing for both Botox Cosmetic and Xeomin is 24 units total (12 units per eye), 20 units total (10 units per eye) is one of the most common doses used in clinical practice. In younger patients or individuals with finer dynamic lines, 20 units provides robust muscle relaxation while preserving natural, subtle expressive movement.

Why did my crow's feet come back after only 2 months?

Crow's feet often wear off faster than forehead lines because the orbicularis oculi contracts continuously (over 14,000 involuntary blinks per day). If your results faded in under 8 weeks, common causes include:

1. Under-dosing: Receiving only 4 to 6 units per eye instead of the standard 10 to 12 units.
2. High physical metabolism / vigorous exercise: Daily intense cardiovascular training increases muscular metabolic turnover.
3. Static line confusion: Lines etched into the skin at rest may become noticeable as soon as the initial post-injection edema resolves, creating the false impression that the neurotoxin has "disappeared."

Can filler be used for crow's feet instead of Botox?

No. Dermal fillers (such as hyaluronic acid) should not be injected directly into dynamic crow's feet lines. The periorbital skin is extremely thin; injecting filler into lateral canthal creases frequently results in the Tyndall effect (visible blue discoloration), visible superficial beads/lumps, and lymphatic blockage that creates chronic under-eye puffiness. Dynamic lines require neurotoxins to relax muscle folding; etched static lines require resurfacing lasers or chemical peels.

Why is there still no Botox cream—were topical versions not tried?

Topical botulinum toxin creams and gels were extensively researched in at least nine clinical trials (including Revance's RT001 program and Anterios's ANT-1207). Every program failed because botulinum neurotoxin is a massive 150 kDa protein complex—roughly 1,800 times larger than the skin's 500-Dalton transdermal absorption limit. Large proteins cannot passively penetrate the stratum corneum lipid barrier to reach the underlying muscle without percutaneous needle delivery.

---

Sources

• DailyMed — BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information (FDA-Approved Label): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab
• DailyMed — XEOMIN (incobotulinumtoxinA) Prescribing Information (FDA-Approved Label): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f35d6e0-3450-4abc-a0da-cc7b277e7c6e
• ClinicalTrials.gov — A Phase 3 Study of IncobotulinumtoxinA in Upper Facial Lines (Trial 1071): https://clinicaltrials.gov/study/NCT04594213
• ClinicalTrials.gov — A Study to Evaluate RT001 Topical Gel in Lateral Canthal Lines (Phase 2): https://clinicaltrials.gov/study/NCT00968825
• ClinicalTrials.gov — Dose-Escalation Study of DaxibotulinumtoxinA for Injection in Lateral Canthal Lines: https://clinicaltrials.gov/study/NCT03911102
• American Society of Plastic Surgeons — 2023 Plastic Surgery Statistics Report: https://www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin
• StatPearls — Botulinum Toxin (Mechanism, Dosing, and Safety Overview): https://www.ncbi.nlm.nih.gov/books/NBK557387/
• StatPearls — Tretinoin (Topical Retinoid Clinical Pharmacology): https://www.ncbi.nlm.nih.gov/books/NBK557478/